The Impact of Cardiovascular Risk, Baseline LDL-Cholesterol, Treatment Dose and Adherence on Cost-Effectiveness of Statins in Newly Diagnosed Diabetes Patients

被引：0
|
作者：
de Vries, Dianna [1 ]
Hak, Eelko [1 ]
Postma, Maarten J. [1 ]
机构：
[1] Univ Groningen, PharmacoEpidemiol & PharmacoEcon, Groningen, Netherlands
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2015年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
63
引用
收藏
页码：37 / 38
页数：2
相关论文
共 50 条
  • [21] TUMOR TREATING FIELDS TREATMENT FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: A COST-EFFECTIVENESS ANALYSIS FOR SWEDEN
    Guzauskas, G. F.
    Wang, B. C. M.
    Kinzel, A.
    Proescholdt, C.
    NEURO-ONCOLOGY, 2018, 20 : 256 - 256
  • [22] Prevention of renal failure in Chinese patients with newly diagnosed type 2 diabetes: A cost-effectiveness analysis
    Wu, Bin
    Zhang, Suhua
    Lin, Houwen
    Mou, Shan
    JOURNAL OF DIABETES INVESTIGATION, 2018, 9 (01): : 152 - 161
  • [23] Prescribing patterns, adherence and LDL-cholesterol response of type 2 diabetes patients initiating statin on low-dose versus standard-dose treatment: a descriptive study
    de Vries, F. M.
    Voorham, J.
    Hak, E.
    Denig, P.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2016, 70 (06) : 482 - 492
  • [24] Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States
    Gandra, Shravanthi R.
    Villa, Guillermo
    Fonarow, Gregg C.
    Lothgren, Mickael
    Lindgren, Peter
    Somaratne, Ransi
    van Hout, Ben
    CLINICAL CARDIOLOGY, 2016, 39 (06) : 313 - 320
  • [25] COST-EFFECTIVENESS OF LDL-C LOWERING WITH EVOLOCUMAB IN PATIENTS WITH HIGH CARDIOVASCULAR RISK IN THE UNITED STATES
    Gandra, S. R.
    Villa, G.
    Fonarow, G.
    Lothgren, M.
    Lindgren, P.
    Somaratne, R.
    van Hout, B.
    VALUE IN HEALTH, 2016, 19 (03) : A3 - A3
  • [26] Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk: The influence of baseline medication on LDL-cholesterol, blood pressure and calculated risk reduction when switching to a cardiovascular polypill
    Lafeber, Melvin
    Spiering, Wilko
    Visseren, Frank L. J.
    Grobbee, Diederick E.
    Bots, Michiel L.
    Stanton, Alice
    Patel, Anushka
    Prabhakaran, Dorairaj
    Webster, Ruth
    Thom, Simon
    Rodgers, Anthony
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2017, 24 (09) : 951 - 961
  • [27] Modeling the cost-effectiveness of ilaprazole versus omeprazole for the treatment of newly diagnosed duodenal ulcer patients in China
    Xuan, J. W.
    Song, R. L.
    Xu, G. X.
    Lu, W. Q.
    Lu, Y. J.
    Liu, Z.
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (11) : 1056 - 1060
  • [28] Strategies to Screen for Diabetic Retinopathy in Chinese Patients with Newly Diagnosed Type 2 Diabetes A Cost-Effectiveness Analysis
    Wu, Bin
    Li, Jin
    Wu, Haixiang
    MEDICINE, 2015, 94 (45) : e1989
  • [29] Cost-effectiveness in Italy of preventive treatment with ramipril in patients at high risk of cardiovascular events
    Capri, S
    Perlini, S
    CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (06) : 913 - 921
  • [30] Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk
    Kohli-Lynch, Ciaran N.
    Bellows, Brandon K.
    Thanassoulis, George
    Zhang, Yiyi
    Pletcher, Mark J.
    Vittinghoff, Eric
    Pencina, Michael J.
    Kazi, Dhruv
    Sniderman, Allan D.
    Moran, Andrew E.
    JAMA CARDIOLOGY, 2019, 4 (10) : 969 - 977
12345